PITPNC1

PITPNC1 is a Class II phosphatidylinositol transfer protein that couples lipid sensing to vesicular secretion, metabolic reprogramming, and signaling in both normal physiology and cancer. It selectively binds and transfers phosphatidylinositol (PI) and phosphatidic acid (PA) but not phosphatidylcholine, and its lipid cargo is influenced by phospholipase D activity (PMID:22822086). At the Golgi, PITPNC1 engages PI4P and recruits RAB1B, which in turn localizes GOLPH3 to drive Golgi extension and enhanced vesicular secretion of pro-invasive and pro-angiogenic mediators such as MMP1 and PDGFA (PMID:26977884). PITPNC1 protein stability is controlled by 14-3-3 binding to phosphorylated C-terminal PEST motifs that shield it from proteasomal degradation (PMID:21728994), and in KRAS-driven cancers it is transcriptionally upregulated via MEK/JNK signaling to stabilize MYC, direct mTOR localization, and suppress autophagy (PMID:37210549).

1. 2011 High

   Establishing how PITPNC1 protein turnover is controlled resolved the previously unknown regulatory logic of a Class II PITP: 14-3-3 binding to dual phosphoserine sites shields C-terminal PEST sequences from ubiquitin–proteasome degradation, and the PITP domain can be membrane-recruited through interaction with the integral membrane protein ATRAP.

   Evidence Co-immunoprecipitation, phosphosite mutagenesis, pulse-chase degradation kinetics, and proteasome-inhibitor rescue in cultured cells

   PMID:21728994

   Open questions at the time

   • Kinases responsible for Ser274/Ser299 phosphorylation are unidentified
   • Physiological contexts that trigger ATRAP–PITPNC1 interaction are unexplored
   • Whether 14-3-3 binding alters lipid transfer activity is untested
2. 2011 High

   Identifying PITPNC1 as a functional target of miR-126 in metastatic breast cancer established it as a mediator of metastatic angiogenesis and colonization, positioning it within the broader miR-126/IGFBP2/MERTK network.

   Evidence miRNA overexpression, PITPNC1 knockdown, epistasis rescue, in vitro endothelial recruitment and in vivo metastasis assays

   PMID:22170610

   Open questions at the time

   • Direct transcriptional versus post-transcriptional regulation by miR-126 on PITPNC1 mRNA not dissected at the binding-site level
   • Relative contribution of PITPNC1 versus IGFBP2 and MERTK to metastatic phenotype is not quantitatively resolved
3. 2012 High

   Defining the lipid specificity of PITPNC1 answered whether Class II PITPs share the phosphatidylcholine-transfer capacity of Class I PITPs: PITPNC1 transfers PA and PI but not PC, and phospholipase D activation shifts the cargo equilibrium from PI toward PA.

   Evidence Purified recombinant protein from E. coli, in vitro lipid transfer assays, permeabilized HL60 cell reconstitution, lipid mass spectrometry

   PMID:22822086

   Open questions at the time

   • Structural basis for PA selectivity over PC is unknown
   • In vivo lipid cargo under physiological conditions has not been validated
   • Whether PA transfer has a dedicated cellular function distinct from PI transfer is unresolved
4. 2016 High

   Connecting PITPNC1's lipid-binding activity to a specific organelle-level output resolved how it drives malignant secretion: PITPNC1 binds Golgi PI4P, recruits RAB1B, which localizes GOLPH3 to extend Golgi membranes and enhance vesicular secretion of pro-invasive/pro-angiogenic cargo.

   Evidence PI4P-binding assays, Co-IP of RAB1B and GOLPH3, subcellular fractionation, knockdown epistasis, secreted-proteome mass spectrometry in cancer cells

   PMID:26977884

   Open questions at the time

   • Whether PITPNC1 directly presents PI4P to RAB1B or acts via an intermediate is unknown
   • Contribution of PA transfer versus PI4P sensing to Golgi phenotype is not separated
   • Regulation of PITPNC1 Golgi targeting is not defined
5. 2018 Medium

   Demonstrating that PITPNC1 promotes anoikis resistance through fatty acid oxidation expanded its role beyond lipid transfer to metabolic reprogramming, linking the omental adipocyte microenvironment to PITPNC1-mediated upregulation of CD36 and CPT1B in gastric cancer.

   Evidence siRNA/overexpression, co-culture with adipocytes, FAO inhibitor rescue, in vivo metastasis models in gastric cancer

   PMID:30555557

   Open questions at the time

   • Mechanism by which PITPNC1 upregulates CD36/CPT1B transcription is not defined
   • Whether lipid transfer activity is required for FAO enhancement is untested
   • Single-lab finding without independent replication
6. 2022 Medium

   Knockout mouse phenotyping revealed a physiological requirement for PITPNC1 in brown adipose tissue thermogenesis, linking its phospholipid homeostasis function to mitochondrial β-oxidation in vivo: Pitpnc1−/− mice accumulate PC and lose PA in brown adipocytes, causing cold intolerance.

   Evidence Pitpnc1 global knockout mice, acute cold exposure, lipidomics, mitochondrial function assays

   PMID:36166181

   Open questions at the time

   • Whether the phenotype is cell-autonomous to brown adipocytes versus systemic is not resolved
   • Molecular mechanism connecting PA depletion to defective β-oxidation is uncharacterized
   • Single-lab study
7. 2023 Medium

   Placing PITPNC1 downstream of KRAS via MEK/JNK signaling and upstream of MYC stabilization and mTOR localization unified its oncogenic functions: PITPNC1 acts as a KRAS effector that suppresses autophagy and promotes proliferation in lung and pancreatic cancers.

   Evidence Genetic KRAS modulation, pharmacological MEK/JNK inhibition, RNA-seq, protein localization, in vivo tumor models

   PMID:37210549

   Open questions at the time

   • Direct biochemical mechanism by which PITPNC1 stabilizes MYC protein is unknown
   • Whether lipid transfer activity is required for MYC/mTOR axis is untested
   • Relationship between Golgi secretion function and KRAS/MYC/mTOR axis is not integrated
8. 2024 Medium

   Identifying a PITPNC1/FASN/CD155 axis in radioresistant colorectal cancer showed that PITPNC1 can modulate immune evasion by regulating surface checkpoint ligand expression, with functional consequences for CD8+ T cell cytotoxicity.

   Evidence Co-IP and co-localization of PITPNC1–FASN–CD155, siRNA knockdown, co-culture with CD8+ T cells, in vivo tumor models

   PMID:38291470

   Open questions at the time

   • Mechanism linking PITPNC1 to FASN-dependent CD155 surface expression is indirect
   • Whether lipid transfer or scaffolding mediates the interaction is unknown
   • Single-lab finding

• A unifying structural and biochemical model explaining how PITPNC1 lipid transfer specificity (PA vs PI vs PI4P) is coupled to its diverse downstream outputs — Golgi secretion, metabolic reprogramming, MYC stabilization, and immune modulation — remains unresolved.
• No crystal structure of PITPNC1 with bound lipid cargo exists
• Whether distinct lipid cargoes mediate distinct cellular functions is untested
• Integration of PITPNC1 phospholipid homeostasis role with its oncogenic signaling role has not been attempted